Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Julius-Maximilians-Universität Würzburg maintains a portfolio with 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. Prosecution is distributed across 9 distinct examiners and 9 distinct art units. The busiest examiner for this entity is BUTTICE, AUDREY L, who is responsible for 2 busiest examiner pending actions.
The ratio of 9 distinct examiners to 10 pending office actions suggests a broad distribution of subject matter. With 9 distinct art units involved, the university's patent strategy covers multiple technical classifications. BUTTICE, AUDREY L handles 2 busiest examiner pending actions, while the other pending actions are spread among the remaining distinct examiners. This distribution indicates that most examiners are handling only one matter each for the university.
Managing 10 pending office actions across 9 distinct art units requires coordination across multiple USPTO divisions. The Biotechnology & Pharmaceuticals technology area encompasses all 10 pending office actions. Practitioners must account for the perspectives of 9 distinct examiners when navigating this portfolio. The presence of 2 busiest examiner pending actions under BUTTICE, AUDREY L represents the highest concentration of matters for any single examiner in this portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 1 (10%) |
| Multi-statute (no §101) | 5 (50%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 2 | 47.9% | +25.9% |
| EDWARDS, LYDIA E | 1 | 60.2% | +5.8% |
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18058347 | CONTROL AND MODULATION OF THE FUNCTION OF GENE-MODIFIED CHIMERIC ANTIGEN RECEPTOR T CELLS WITH DASATINIB AND OTHER TYROSINE KINASE INHIBITORS | JARRELL, NOBLE E | 77d overdue |
| 17619569 | ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN | MIDDLETON, DANAYA L | 28d overdue |
| 18019238 | SIGLEC-6-BINDING POLYPEPTIDES | JUEDES, AMY E | 26d |
| 18145837 | USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA | BUTTICE, AUDREY L | — |
| 17914062 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17619569 | ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN | MIDDLETON, DANAYA L | 28d overdue |
| 18019238 | SIGLEC-6-BINDING POLYPEPTIDES | JUEDES, AMY E | 26d |
| 18685658 | ANTIBODIES AGAINST CANDIDA ALBICANS PROTEINS AND THEIR THERAPEUTIC AND PROPHYLACTIC USE FOR TREATING AND PREVENTING INVASIVE FUNGAL INFECTIONS | BUTTICE, AUDREY L | — |
| 18145837 | USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA | BUTTICE, AUDREY L | — |
| 17914062 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | BENAVIDES, JENNIFER ANN | — |
| 17475189 | ROR1-SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CAR) WITH HUMANIZED TARGETING DOMAINS | NICOL, ALEXANDER W | — |
| 17431903 | CELL PENETRATING TRANSPOSASE | QIAN, CELINE X | — |
| 16645072 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| 1699 | 1 |
| 1675 | 1 |
| 1674 | 1 |
| 1634 | 1 |
| 1637 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685658 | ANTIBODIES AGAINST CANDIDA ALBICANS PROTEINS AND THEIR THERAPEUTIC AND PROPHYLACTIC USE FOR TREATING AND PREVENTING INVASIVE FUNGAL INFECTIONS | BUTTICE, AUDREY L | — | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18554322 | DEVICE FOR FABRICATING A PERFUSABLE THREE-DIMENSIONAL TISSUE CONSTRUCT | EDWARDS, LYDIA E | 1796 | §103 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18019238 | SIGLEC-6-BINDING POLYPEPTIDES | JUEDES, AMY E | 1644 | §102§103§112Other | Final Rejection | 26d | Pending | Feb 01, 2023 |
| 18145837 | USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | — | Pending | Dec 22, 2022 |
| 18058347 | CONTROL AND MODULATION OF THE FUNCTION OF GENE-MODIFIED CHIMERIC ANTIGEN RECEPTOR T CELLS WITH DASATINIB AND OTHER TYROSINE KINASE INHIBITORS | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | 77d overdue | Pending | Nov 23, 2022 |
| 17914062 | COMBINATION THERAPY OF ATRA OR OTHER RETINOIDS WITH IMMUNOTHERAPEUTIC AGENTS BINDING TO BCMA | BENAVIDES, JENNIFER ANN | 1675 | §102§103 | Non-Final OA | — | Pending | Sep 23, 2022 |
| 17619569 | ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN | MIDDLETON, DANAYA L | 1674 | §103§112Other | Non-Final OA | 28d overdue | Pending | Dec 15, 2021 |
| 17475189 | ROR1-SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CAR) WITH HUMANIZED TARGETING DOMAINS | NICOL, ALEXANDER W | 1634 | §103 | Non-Final OA | — | Pending | Sep 14, 2021 |
| 17431903 | CELL PENETRATING TRANSPOSASE | QIAN, CELINE X | 1637 | Other | Non-Final OA | — | Pending | Aug 18, 2021 |
| 16645072 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | STEADMAN, DAVID J | 1656 | §103 | Non-Final OA | — | Pending | Mar 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial